- Home
- ANTX vs CLPS Comparison
ANTX vs CLPS Comparison
Compare ANTX & CLPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- CLPS
- Stock Information
- Founded
- ANTX 2017
- CLPS 2005
- Country
- ANTX United States
- CLPS Hong Kong
- Employees
- ANTX N/A
- CLPS 3325
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- CLPS Computer Software: Prepackaged Software
- Sector
- ANTX Health Care
- CLPS Technology
- Exchange
- ANTX Nasdaq
- CLPS Nasdaq
- Market Cap
- ANTX 33.2M
- CLPS 26.0M
- IPO Year
- ANTX 2022
- CLPS 2018
- Fundamental
- Price
- ANTX $1.10
- CLPS $1.00
- Analyst Decision
- ANTX Buy
- CLPS
- Analyst Count
- ANTX 2
- CLPS 0
- Target Price
- ANTX $2.00
- CLPS N/A
- AVG Volume (30 Days)
- ANTX 95.4K
- CLPS 9.8K
- Earning Date
- ANTX 08-12-2025
- CLPS 03-05-2025
- Dividend Yield
- ANTX N/A
- CLPS 13.00%
- EPS Growth
- ANTX N/A
- CLPS N/A
- EPS
- ANTX N/A
- CLPS N/A
- Revenue
- ANTX N/A
- CLPS $153,816,045.00
- Revenue This Year
- ANTX N/A
- CLPS N/A
- Revenue Next Year
- ANTX N/A
- CLPS N/A
- P/E Ratio
- ANTX N/A
- CLPS N/A
- Revenue Growth
- ANTX N/A
- CLPS 5.81
- 52 Week Low
- ANTX $0.87
- CLPS $0.68
- 52 Week High
- ANTX $3.07
- CLPS $1.70
- Technical
- Relative Strength Index (RSI)
- ANTX 48.42
- CLPS 57.62
- Support Level
- ANTX $1.05
- CLPS $0.94
- Resistance Level
- ANTX $1.10
- CLPS $1.03
- Average True Range (ATR)
- ANTX 0.04
- CLPS 0.04
- MACD
- ANTX 0.00
- CLPS 0.01
- Stochastic Oscillator
- ANTX 50.00
- CLPS 82.70
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About CLPS CLPS Incorporation
CLPS Inc is a holding company. The company through its subsidiaries provides information technology consulting and solutions institutions in the banking, insurance, and financial sectors, both in China and globally. Its products are Risk Control Platform, Transaction Acquiring Platform, Debt Collection Platform, Virtual Bank Training Platform, Credit Card System, and other related products. The company generates its revenue from IT consulting services, Customized IT solution services, and others. Generating the majority of its revenue from the IT consulting service.